Cullinan Oncology's (CGEM) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Cullinan Oncology (NASDAQ:CGEM – Get Rating) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $50.00 price objective on the stock. Separately, Morgan Stanley dropped their price objective on Cullinan Oncology from $27.00 to $19.00 and set an overweight […]

Related Keywords

United States , ,Nisa Investment Advisors ,Barclays Plc ,Morgan Stanley ,Annandale Capital ,Cullinan Oncology Inc ,Tang Capital Management ,Cullinan Oncology ,Get Rating ,Investment Advisors ,Capital Management ,Oncology Inc ,Cullinan Oncology Daily ,Nasdaq Cgem ,Cgem ,Medical ,Reiterated Rating ,Hc Wainwright ,